<DOC>
	<DOCNO>NCT00452166</DOCNO>
	<brief_summary>30 non-diabetic , non-obese patient stage 4 chronic kidney disease ask participate metabolic study . The primary aim study determine effect rosiglitazone insulin resistance non-obese patient non-diabetic stage 4 CKD . Secondary end point effect inflammation ( hsCRP ) , lipid profile , bone density body composition .</brief_summary>
	<brief_title>Rosiglitazone Insulin Resistance Renally Impaired Patients</brief_title>
	<detailed_description>This part study perform 30 non-diabetic non-obese patient . In study patient receive single-dose oral placebo rosiglitazone daily take morning . During first 8 week patient dose 4 mg rosiglitazone . Then concentration serum transaminase check within acceptable range , dose double remainder study . If change serum transaminase consider clinically significant patient withdrawn study transaminase increase clinically significant level treatment patient may continue 4 mg daily dose . The insulin sensitivity measure use euglycaemic hyperinsulinaemic clamp technique , validate technique . Screening eligible patient : fast glucose ≤ 7,0 mmol/L BMI ≤ 30 . Exclusion criterion : - A diagnosis diabetes mellitus patient us insulin ; - Significant co-morbidities , accord treat nephrologists , make unlikely patient able complete foreseen study period ; - Significant cardiovascular co-morbidities likely interfere objective study ( morbid obesity , family history dyslipidemia , etc . ) ; discretion treat nephrologists principal investigator ; - Allergy PPAR 's ; - Cardiac disease mark limitation functional capacity ( New York Heart Association III IV clinical status ) ; - Use immunosuppressant agent ; - History renal transplant ; - Hepatic insufficiency ( defined transaminase concentration &gt; 2.5 time upper limit normal laboratory ) ; - A history alcohol abuse excessive alcohol use define 21 consumption per week ; - For female patient : pregnancy , intention become pregnant within study period , lactate patient Eligible patient receive insulin ( Actrapid ; Novo Nordisk A/S , Copenhagen , Denmark ) infusion rate 40 mU ( 288 pmol ) /kg/m2 body surface area per minute . Euglycemia ( target blood concentration 5 mM ) maintain adjust rate 20 % glucose infusion accord whole blood glucose concentration measure arterialized venous blood ; patient keep right arm box contain heat air ( 60°C ) . Insulin glucose infused left arm . In healthy subject , hepatic glucose production completely suppress serum insulin level &gt; 60 mU/L . Here expect insulin level serum 80 mU/L . Blood sample draw 5 min interval determination blood glucose , 10 min interval period 90 -120 min determination serum insulin free fatty acid . The insulin-sensitivity index ( ISI ) calculate dividing average glucose-infusion rate mean steady-state serum insulin level period 90 -120 min . In addition glucose-infusion rate insulin sensitivity index , influence clamp level FFA also assed . At baseline follow-up study inflammatory parameter ( hsCRP ) lipid measure . At baseline end bone densitometry ( DEXA ) perform .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>CKD stage 4 BMI ≤ 30 Fasting glucose &lt; 7 mmol/l Exclusion patient take place case : A diagnosis diabetes mellitus patient us insulin Significant comorbidities , accord treat nephrologists , make unlikely patient able complete foreseen study period Significant cardiovascular comorbidities likely interfere objective study ( morbid obesity , family history dyslipidemia , etc . ) ; discretion treat nephrologists principal investigator Allergy PPAR 's Cardiac disease mark limitation functional capacity ( New York Heart Association III IV clinical status ) Use immunosuppressant agent History renal transplant Hepatic insufficiency ( defined transaminase concentration &gt; 2.5 time upper limit normal laboratory ) A history alcohol abuse excessive alcohol use define 21 consumption per week For female patient : pregnancy , intention become pregnant within study period , lactate patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>